ATX 13.6% 10.0¢ amplia therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-29

  1. 831 Posts.
    lightbulb Created with Sketch. 206
    I think it'd have to be FOLFIRINOX.

    Point 2 is very valid and makes you think that ATX would really struggle to run a trial like that - It leads you think it'd be a takeover pre-phase 3.
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.